All Insights
Showing 1 - 12 of 759
Intellectual property
The InterDigital and Amazon SEP saga heats up with latest Unified Patent Court judgments
UPC confirms wide anti-suit-style protection against interim-licence relief, suggesting it could extend to final relief
Life Sciences and Healthcare
Planned EU medtech changes and codified Helsinki procedure support consistent qualification and classification
EU coordination, expert panel opinions and targeted down classification are proposed to harmonise risk based outcomes
Life Sciences and Healthcare
EU drug agency to take broader coordinating role in devices and diagnostics in latest proposal
Expert panel support, shortage coordination and combined study procedures strengthen the EMA's oversight of devices
Regulatory Outlook
Advertising and marketing | UK Regulatory Outlook January 2026
Influencer marketing | AI disclosure and enforcement | Protection of children | Price transparency under the DMCCA | Subscriptions |
Life Sciences and Healthcare
EU revised device rules rebalance compliance towards simplification and proportionality
Commission proposal would streamline MDR and IVDR duties with flexible evidence, timeless certificates and tailored risk rules
Knowledge Notes
What business law changes can the UK expect in 2026?
Osborne Clarke's Knowledge Team looks at what's in store for business
Intellectual property
English court maintains anti-anti-suit relief and dismisses InterDigital's jurisdiction challenge
Case will proceed to a final RAND determination after the jurisdiction challenge dismissed, with interim relief to protect the proceedings
Advertising and marketing regulation
Marketinglaw: December 2025
Welcome to the latest edition of Marketinglaw
The Digital Markets Competition and Consumers Act (DMCCA)
UK CMA finalises guidance on price transparency under DMCCA and begins enforcement action
From holidays to fashion, fourteen sectors under scrutiny as the regulator finalises guidance on total price requirements
Life Sciences and Healthcare
The US BIOSECURE Act: is your supply chain at risk?
The legislation could be enacted by the end of the year, with potentially wide-ranging consequences for biotech companies undertaking federal
